Edition:
United States

RTI Surgical Inc (RTIX.OQ)

RTIX.OQ on NASDAQ Stock Exchange Global Select Market

4.20USD
14 Dec 2017
Change (% chg)

-- (--)
Prev Close
$4.20
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
34,444
52-wk High
$6.00
52-wk Low
$3.03

Summary

Name Age Since Current Position

Curtis Selquist

71 2016 Chairman of the Board

Camille Farhat

47 2017 Chief Executive Officer

Peter Gearen

66 2016 Vice Chairman of the Board

Jonathon Singer

52 2017 Chief Financial Officer, Chief Administrative Officer, Director

Roger Rose

55 2014 Executive Vice President - Tissue-Based Implants, President - RTI Donor Services

Thomas Rose

2014 Corporate Secretary

Thomas McEachin

2015 Director

Mark Stolper

2017 Director

Christopher Sweeney

2015 Director

Paul Thomas

61 2016 Director

Nicholas Valeriani

60 2016 Director

Philip Chapman

53 1998 Independent Director

Adrian Smith

71 2008 Independent Director

Shirley Weis

62 2014 Independent Director

Biographies

Name Description

Curtis Selquist

Mr. Curtis M. Selquist is Chairman of the Board of RTI Surgical, Inc., Mr. Curt Selquist joined the Board of Directors pursuant to the Investment Agreement by and between the Company and WSHP Biologics Holdings, LLC, an affiliate of Water Street Healthcare Partners, in July 2013. Mr. Selquist is an operating partner at Water Street. Mr. Selquist has led and grown a number of global healthcare businesses during a distinguished 35-year career at Johnson & Johnson. Prior to joining Water Street, he was the company group chairman of Johnson & Johnson Medical and Johnson & Johnson Healthcare Systems. Mr. Selquist also served as president of Johnson & Johnson Latin America. He was subsequently appointed worldwide president of Johnson & Johnson, Merck Consumer Pharmaceuticals and company group chairman, responsible for Johnson & Johnson Medical. Mr. Selquist is the founding chairman of the Global Healthcare Exchange. He also served as chairman of the National Alliance for Health Information Technology, and as a board member of the National Quality Forum. He chaired its Leadership Network. Mr. Selquist serves as the lead director of Breg. He is also the board chair of Temp Time, Inc.

Camille Farhat

Mr. Camille Farhat has been appointed as Chief Executive Officer of the Company, effective March 15, 2017. He previously served as president and CEO of American Medical Systems, Inc. (AMS), an operating business of Endo International plc (NASDAQ/TSX: ENDP). In this role, he realigned the business to fund innovation, expand internationally and resume growth, ultimately leading to Boston Scientific's $1.65 billion acquisition of the Men's and Prostate Health businesses. Mr. Farhat's expertise aligns with RTI's focus on developing and delivering exceptional products for patients and achieving sustainable, long-term growth. He has a track record of revitalizing and profitably growing global businesses within the health care industry. Prior to AMS, Mr. Farhat held senior leadership roles where he improved the performance of business units at companies including Baxter Healthcare, Medtronic, Inc. and General Electric. Mr. Farhat has broad global leadership experience, with senior-level assignments in 10 countries during the past 22 years. Prior to AMS, he advanced several business segments for Baxter. He was global general manager of Baxter's largest division, Baxter Pharmaceuticals and Therapies, where he drove significant improvements in the performance and operating efficiency of the business, helping to transform it into Baxter's top-performing business unit. In a previous role, Mr. Farhat successfully turned around Baxter's Global Infusion Systems business division under a consent decree. Mr. Farhat also served as vice president of business development at Medtronic and as global general manager of the company's Gastroenterology and Urology divisions. Mr. Farhat earned an M.B.A. from Harvard University, a degree in European Union studies from Institut National d'Etudes Politiques de Paris and a B.S., B.A. in finance and accounting from Northeastern University.

Peter Gearen

Dr. Peter F. Gearen, M.D. is Vice Chairman of the Board of RTI Surgical, Inc. (formerly known as RTI Biologics, Inc.). Dr. Gearen was Chief of Staff at the Shands Hospital at the University of Florida and served as Assistant Dean of Clinical Affairs at the University of Florida College of Medicine from 1992 until 1999. Dr. Gearen also has been an Associate Professor of Orthopedics at the University of Florida College of Medicine since 1993. Dr. Gearen was appointed Chairman of the Department of Orthopedics in May 2002 and stepped down as Chairman on June 30, 2010. Dr. Gearen holds a B.A. from Spring Hill College and an M.D. from the Stritch Loyola Medical School.

Jonathon Singer

Mr. Jonathon M. Singer has been re-appointed as Chief Financial Officer, Chief Administrative Officer, Director of the company with effective October 2, 2017. He is as a sitting chief financial officer of a publicly-traded company and as a certified public accountant with experience at a big four accounting firm) and life sciences experience makes him well-qualified to serve on our board. Mr. Singer has served as CFO of Sagent Pharmaceuticals since September 2011, and was appointed executive vice president and CFO in March 2012. Mr. Singer was senior vice president, treasurer, secretary and CFO of Landauer Inc. from 2006 to 2011. From 2004 to 2006, Mr. Singer served as vice president of global finance and CFO of the Medical Segment for Teleflex Inc. Prior to 2004, Mr. Singer worked in various capacities for R.R. Donnelley & Sons, Cardinal Health Inc., and KPMG LLP.

Roger Rose

Mr. Roger W. Rose Jr. is the President - RTI Donor Services, Executive Vice President - Tissue-Based Implants of RTI Surgical, Inc., (formerly known as RTI Biologics, Inc.). He joined RTI as vice president of donor services in October 2002 and assumed additional responsibility for distribution and marketing in October 2003. In August 2004 he was named executive vice president with RTI and, in February 2008, he was named president of RTI Donor Services, RTI’s not-for-profit affiliate. In June 2010, Rose was named RTI’s executive vice president and chief commercial officer. In his current position, Rose oversees all U.S. direct distribution and marketing activity, including spine, biologics, sports medicine, surgical specialties and general orthopedic. Rose also oversees all aspects of RTI Donor Services, including marketing and the distribution of donated tissue back into the community. He is committed to ensuring a meaningful connection between the donation and transplantation communities. Prior to joining RTI, Rose spent seven years at Stryker Corporation, headquartered in Kalamazoo, Mich., where he held leadership positions in sales and marketing in the medical and orthopedic divisions. He earned a bachelor’s degree in business administration from Western Michigan University, Kalamazoo, and completed numerous executive education courses focusing on finance, leadership, medical marketing, negotiation and strategy at UCLA, Los Angeles; University of Michigan, Ann Arbor, Mich.; and Harvard Business School, Boston.

Thomas Rose

Mr. Thomas F. Rose CPA is Corporate Secretary of RTI Surgical, Inc. He was Executive Vice President- Administration, Secretary of RTI Surgical, Inc. (formerly known as RTI Biologics, Inc.). Since July 2013. He also serves as Corporate Secretary to the Board of Directors. Rose joined the company as Vice President and Chief Financial Officer in May 2002 and served as Executive Vice President and Chief Financial Officer until June 2010 when he was named Executive Vice President and Chief Operations Officer. Rose served the previous 10 years as Vice President and Chief Financial Officer at A.M. Todd Group. Rose earned a bachelor’s degree in business administration from Western Michigan University and is a Certified Public Accountant. He has also completed numerous executive education courses at University of Michigan and Northwestern University focusing on strategy and organizational issues.

Thomas McEachin

Mr. Thomas A. McEachin is Director of RTI Surgical, Inc. Mr. McEachin has been retired since 2012. Prior to his retirement, he served in executive capacities with Covidien Surgical Solutions, a division of Covidien plc, from 2008-2012, first as Vice President of Finance (2008-2011) and then as Vice President and Group Chief Financial Officer (2011-2012). Prior to joining Covidien, Mr. McEachin served United Technologies and its subsidiaries in various capacities during the period 1997-2008. He served as Vice President and Corporate Controller of Hamilton Sundstrand (2006-2008); Vice President and Chief Financial Officer of UTC Power (2003-2006); Director of Investor Relations (chief investor relations officer) of United Technologies (2001-2003); Vice President and Controller of Pratt & Whitney (1999-2001) and was head of Internal Audit of United Technologies (1997-1999). Prior to joining United Technologies, Mr. McEachin served in various executive capacities with Digital Equipment Corporation (1986-1997), and Xerox Corporation (1975-1986). Mr. McEachin holds a B.Sc. from New York University and an MBA from Stanford University.

Mark Stolper

Christopher Sweeney

Mr. Christopher R. Sweeney is Director of RTI Surgical, Inc. He is a partner of Water Street Healthcare Partners (“Water Street”), was appointed to serve on the Company’s board of directors, effective immediately, as a designee of its preferred shareholder, Water Street. He will hold office until he is removed by action of the preferred shareholder or his earlier death, resignation, retirement or disqualification. Mr. Sweeney has been employed by Water Street, a strategic investor focused exclusively on the healthcare industry, since 2005, initially as a principal and since 2010 as a partner. Prior to joining Water Street, Mr. Sweeney was employed in various capacities with Cleary & Oxford, a middle market healthcare investment firm from 1997-2005, ultimately serving as a principal. Mr. Sweeney holds a degree from Williams College.

Paul Thomas

Mr. Paul G. Thomas has appointed as Director of the company. effective May 26, 2016. He was the founder of Roka Bioscience Inc. and has served as its CEO since September 2009. He also sits on the board of directors of Roka Bioscience. Prior to Roka Bioscience, Mr. Thomas previously served as chairman, CEO and President of LifeCell Corporation, a publicly traded regenerative medicine company, from 1998 until it was acquired by Kinetic Concepts, Inc. in 2008. Prior to joining LifeCell, Mr. Thomas held various senior positions during his tenure of 15 years with Ohmeda Inc., a world leader in inhalation anesthetics and acute care pharmaceuticals. Mr. Thomas currently serves on the board of directors of AbioMed Inc. and Aegerion Pharmaceuticals Inc.

Nicholas Valeriani

Mr. Nicholas J. Valeriani has appointed as Director of the company. effective May 26, 2016. His prior experience includes serving as the CEO of West Health, The Gary and Mary West Health Institute, a position he held from 2012 to 2015. Previously, Mr. Valeriani served 34 years in key positions at Johnson & Johnson, including company group chairman of Johnson & Johnson Ortho-Clinical Diagnostics from 2009 to 2012; vice president, Office of Strategy and Growth from 2007 to 2009; and, prior to 2007, as worldwide chairman, Medical Devices and Diagnostics, and corporate vice president, Human Resources. Mr. Valeriani also served on the Executive Committee of Johnson & Johnson during his tenure. Mr. Valeriani currently serves on the board of directors of Edwards Lifesciences Corp., Roka Bioscience Inc., as well as the Robert Wood Johnson University Hospital.

Philip Chapman

Mr. Philip R. Chapman is Independent Director of the Company. Mr. Chapman is the President of Venad Administrative Services, Inc., and has been a general partner of Adler & Company since 1995. From 1991 until 1995, Mr. Chapman served as a principal of Adler & Company. From 1988 until 1991, Mr. Chapman served as a senior consultant at Booz Allen & Hamilton International. Mr. Chapman holds a bachelor’s degree and masters of business administration degree from Columbia University.

Adrian Smith

Mr. Adrian John Russell Smith is Independent Director of the Company. Mr. Smith has been the Chief Executive Officer of The Woolton Group since 1997. He is also the Non-Executive Chairman of Premier Credit Ltd, Klean Industries and Harmonic Energy Inc. He is a Non-Executive Director of Byotrol plc and Atlantic Coal plc. His business career includes 13 years in the professional services industry and 24 years with two Fortune 500 companies. He has been a Global Managing Partner, Marketing & Communication at Deloitte Touche Tohmatsu, the Chief Executive Officer of Grant Thornton LLP, and a Managing Partner at Arthur Andersen in the early to mid-1990’s. He held senior international management roles with Ecolab Inc. and also with Procter & Gamble. He serves on the board of the Education Foundation of Indian River County in Florida.

Shirley Weis

Ms. Shirley A. Weis is Independent Director of Rti Surgical, Inc.. Ms. Weis has worked at Mayo Clinic in many different capacities since 1995, but most recently was charged with overseeing the operations of 87 corporations that make up the Mayo Clinic system including a 57,000 member staff. Weis was a member of the Mayo Clinic Board of Trustees and served as the secretary for the Mayo Clinic Board of Governors. She also currently holds a position on the advisory boards of the American World Clinics and Women Business Leaders organizations. Weis is Special Advisor to the President and Professor in the W.P. Carey School of Business and the College of Nursing and Health Innovation at Arizona State University. She graduated with a master’s degree in management from Aquinas College and recently received an honorary doctor of science degree from Michigan State University.